Evidence map›Paper›PMID 42273545›Full record

ReviewChemical science2026

Machine learning-driven cancer diagnostics with improved robustness and interpretability.

Pengfei Li, Zhen Liu

Abstract readReview
In one paragraph

Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pengfei LiState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry, Nanjing University Nanjing 210023 Jiangsu China zhenliu@nju.edu.cn +86-25-8968-5639.ORCID https://orcid.org/0009-0001-9200-1099
Zhen LiuState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry, Nanjing University Nanjing 210023 Jiangsu China zhenliu@nju.edu.cn +86-25-8968-5639.ORCID https://orcid.org/0000-0002-8440-2554

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the leading causes of death worldwide, underscoring the critical need for early diagnosis to improve long-term survival outcomes and reduce mortality rates. Despite significant progress, the development of effective cancer diagnostics continues to face two major challenges. First, the design and optimization of diagnostic assays and analytical workflows largely rely on empirical, trial-and-error approaches, which are inefficient and often yield limited robustness and generalizability. Second, the interpretation of high-dimensional and heterogeneous clinical imaging and molecular profiling data remains complicated, hindering interpretability and the translation of results into clinically actionable insights. Machine learning (ML), with its advanced capabilities in pattern recognition, optimization, and prediction, offers a promising approach to address both challenges for accelerating the development of next-generation cancer diagnostics. In this perspective, we briefly outline the widely used ML algorithms in cancer diagnostics and critically compare their strengths and limitations in real-world applications, considering factors such as data scale, class imbalance, feature structure, generalization performance, and model interpretability. We then summarize recent advances enabled by ML, ranging from analytical platform optimization to multiscale data interpretation. Finally, we discuss remaining challenges and propose a roadmap for future research in ML-driven cancer diagnostics.

Identifiers

PMID42273545
PMCPMC13248645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.